An Interview with Nachum Kaplan, Vice President of Microbiology at Affinium Pharmaceuticals




An Interview with Nachum Kaplan, Vice President of Microbiology at Affinium Pharmaceuticals on bacterial fatty-acid synthesis as a target for AFN-1252: a novel and selective-spectrum antibiotic for the treatment of Staphylococcal infection.
TO READ THE FULL STORY